Keluhan dan Kepatuhan Penderita Malaria Terhadap Pengobatan Malaria Artesunat-Amodiakuin di Kalimantan dan Sulawesi  

Oleh:

Raini, Mariana ; Gitawati, Retno ; Isnawati, Ani ; Tjitra, Emiliana

Jenis: Article from Journal - ilmiah nasional - terakreditasi DIKTI
Dalam koleksi: Media Penelitian dan Pengembangan Kesehatan vol. 21 no. 03 (Sep. 2011), page 111-118.
Topik: malaria; ACT; artesunat-amodiakuin
Fulltext: 92-172-1-SM.pdf (214.29KB)

Ketersediaan

Perpustakaan FK Nomor Panggil: M32.K Non-tandon: 2 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Drug resistance is one of the global problems, particularly in communicable diseases control including Indonesian malaria elimination program. Since 2004, Artesunate-Amodiaquine (AS+AQ), an Artemisinin based Combination Therapy (ACT), has been used in Indonesia as recommended by the WHO for treatment of acute uncomplicated malaria, replacing of chloroquine resistant antimalarial. Since then, implementation of AS+AQ has never been evaluated. It was reported that AS+AQ coverage was 33,7% because the patients did not comply due to adverse events, and the combination therapy was not a single formulation (fixed-dose). Therefore, there is a need to assess and evaluate the compliance of AS+AQ on subjects malaria treated with AS+AQ at Health Center (Puskesmas) sentinel sites in Kalimantan and Sulawesi. This was a cross-sectional and non intervention observational study. There were 99 malaria subjects participated in this study. All subjects were treated with 3 days regimen AS+AQ as the national malaria treatment guideline, and they were followed-up on days 3, 7 and 28. Indepth interview was done in several subjects as informants and staff of puskesmas for knowledge, attitude, practice (KAP) of AS+AQ used. Of the 99 malaria subjects evaluated, there were 34 P. falciparum, 36 P. vivax, and 29 mixed infection malaria subjects. Almost all the study subjects (92,9%) completed the therapy. There were 2 subjects withdrawn due to serious adverse event (SAE), 4 subjects were withdrawn because of having severe untolerable adverse events and 1 subject because of lost to follow up. About 84% subjects experienced clinical complaints after AS+AQ administered. Most of the complaints were mild to moderate and tolerable. Overall, the compliance of the 3-day AS+AQ regimen was moderately satisfied.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali